Mr. Speaker, I thank the parliamentary secretary for the information she has provided on this issue.
I would say that hospitals would welcome the peace of mind that standardized federal regulatory oversight of compounders would bring when it comes to purchasing large quantities of drug preparations for patients in hospitals. This kind of national regulatory oversight would also bring economic benefits; specifically, compounders would be able to demonstrate to potential buyers that their processes and products respect the most stringent national regulatory standards associated with drug manufacturing. In addition, they would be able to operate more efficiently inside the internal Canadian marketplace, as they would be able to avoid having to deal with a costly patchwork of different provincial regulations.